New registry checks migraine drug safety in pregnancy
NCT ID NCT05046613
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows pregnant women with migraine who took rimegepant (Nurtec) and those who did not, to compare rates of birth defects and other pregnancy complications. About 780 participants will be tracked through 12 months after birth. The goal is to gather safety data, not to test a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MIGRAINE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Evidera, a PPD business unit
RECRUITINGWilmington, North Carolina, 28401, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Mind over migraine: brain network may explain why some expect side effects
- The eyes as a window to the brain: can a simple scan monitor MS, Alzheimer's, and Parkinson's?
- Experimental migraine drug JS010 takes first step in human safety trial
- Scientists probe shared pain pathways in endometriosis and migraine
- Brain scans and heat tests may predict migraine in teens
- Could a simple diary ease the burden of migraine?